# Metlife Inc: financial statements, quarterly

MET · NYSE · CIK 1099219 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/met.md) · [Financials](/companies/met/financials.md) · [Filings](/companies/met/filings.md) · [Insiders](/companies/met/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/met/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [0.6](/filings/0001099219-24-000257.md) | [19.0](/filings/0001099219-24-000035.md) | [0.6](/filings/0001099219-25-000135.md) | [0.6](/filings/0001099219-25-000193.md) | [0.6](/filings/0001099219-25-000230.md) | [0.6 d](/filings/0001099219-26-000013.md) | [0.6](/filings/0001099219-26-000035.md) | [0.6](/filings/0001099219-26-000050.md) | [0.6](/filings/0001099219-25-000230.md) | [0.6 d](/filings/0001099219-26-000013.md) | [0.7](/filings/0001099219-26-000035.md) | [0.7](/filings/0001099219-26-000050.md) |
| Operating income | $bn | not reported | not reported | [1.4](/filings/0001099219-25-000135.md) | [1.7](/filings/0001099219-25-000193.md) | [1.4](/filings/0001099219-25-000230.md) | [1.5 d](/filings/0001099219-26-000013.md) | [1.4](/filings/0001099219-26-000035.md) | [1.4](/filings/0001099219-26-000050.md) | [1.7](/filings/0001099219-25-000230.md) | [1.7 d](/filings/0001099219-26-000013.md) | [1.6](/filings/0001099219-26-000035.md) | [1.6](/filings/0001099219-26-000050.md) |
| Interest expense | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $bn | [0.0](/filings/0001099219-24-000257.md) | [0.3 d](/filings/0001099219-26-000013.md) | [0.2](/filings/0001099219-25-000135.md) | [0.2](/filings/0001099219-25-000193.md) | [0.7](/filings/0001099219-25-000230.md) | [0.1 d](/filings/0001099219-26-000013.md) | [0.4](/filings/0001099219-26-000035.md) | [0.2](/filings/0001099219-26-000050.md) | [0.3](/filings/0001099219-25-000230.md) | [0.3 d](/filings/0001099219-26-000013.md) | [0.3](/filings/0001099219-26-000035.md) | [0.3](/filings/0001099219-26-000050.md) |
| Net income | $bn | [0.5](/filings/0001099219-24-000257.md) | [0.6](/filings/0001099219-24-000035.md) | [0.9](/filings/0001099219-25-000135.md) | [0.9](/filings/0001099219-25-000193.md) | [1.3](/filings/0001099219-25-000230.md) | [1.3 d](/filings/0001099219-26-000013.md) | [0.9](/filings/0001099219-26-000035.md) | [0.7](/filings/0001099219-26-000050.md) | [0.9](/filings/0001099219-25-000230.md) | [0.8 d](/filings/0001099219-26-000013.md) | [1.2](/filings/0001099219-26-000035.md) | [0.7](/filings/0001099219-26-000050.md) |
| Diluted EPS | $ per share | [0.56](/filings/0001099219-24-000257.md) | [0.77](/filings/0001099219-24-000035.md) | [1.10](/filings/0001099219-25-000135.md) | [1.28](/filings/0001099219-25-000193.md) | [1.81](/filings/0001099219-25-000230.md) | not reported | [1.28](/filings/0001099219-26-000035.md) | [1.03](/filings/0001099219-26-000050.md) | [1.22](/filings/0001099219-25-000230.md) | not reported | [1.74](/filings/0001099219-26-000035.md) | [1.09](/filings/0001099219-26-000050.md) |
| Basic EPS | $ per share | [0.56](/filings/0001099219-24-000257.md) | [0.78](/filings/0001099219-24-000035.md) | [1.11](/filings/0001099219-25-000135.md) | [1.28](/filings/0001099219-25-000193.md) | [1.82](/filings/0001099219-25-000230.md) | not reported | [1.29](/filings/0001099219-26-000035.md) | [1.04](/filings/0001099219-26-000050.md) | [1.23](/filings/0001099219-25-000230.md) | not reported | [1.75](/filings/0001099219-26-000035.md) | [1.10](/filings/0001099219-26-000050.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [14.9](/filings/0001099219-23-000268.md) | [20.6](/filings/0001099219-25-000044.md) | [19.8](/filings/0001099219-24-000141.md) | [20.8](/filings/0001099219-24-000201.md) | [21.8](/filings/0001099219-24-000257.md) | [20.1](/filings/0001099219-26-000013.md) | [21.3](/filings/0001099219-25-000135.md) | [22.2](/filings/0001099219-25-000193.md) | [20.2](/filings/0001099219-25-000230.md) | [22.0](/filings/0001099219-26-000050.md) | [22.7](/filings/0001099219-26-000035.md) | [19.3](/filings/0001099219-26-000050.md) |
| Total assets | $bn | [652](/filings/0001099219-23-000268.md) | [688](/filings/0001099219-25-000044.md) | [678](/filings/0001099219-24-000141.md) | [676](/filings/0001099219-24-000201.md) | [705](/filings/0001099219-24-000257.md) | [677](/filings/0001099219-26-000013.md) | [688](/filings/0001099219-25-000135.md) | [702](/filings/0001099219-25-000193.md) | [720](/filings/0001099219-25-000230.md) | [745](/filings/0001099219-26-000050.md) | [743](/filings/0001099219-26-000035.md) | [759](/filings/0001099219-26-000050.md) |
| Total liabilities | $bn | [626](/filings/0001099219-23-000268.md) | [657](/filings/0001099219-25-000044.md) | [649](/filings/0001099219-24-000141.md) | [648](/filings/0001099219-24-000201.md) | [674](/filings/0001099219-24-000257.md) | [650](/filings/0001099219-26-000013.md) | [661](/filings/0001099219-25-000135.md) | [675](/filings/0001099219-25-000193.md) | [691](/filings/0001099219-25-000230.md) | [716](/filings/0001099219-26-000050.md) | [715](/filings/0001099219-26-000035.md) | [731](/filings/0001099219-26-000050.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $bn | [0.2](/filings/0001099219-23-000268.md) | [0.1](/filings/0001099219-25-000044.md) | [0.1](/filings/0001099219-24-000141.md) | [0.4](/filings/0001099219-24-000201.md) | [0.4](/filings/0001099219-24-000257.md) | [0.5](/filings/0001099219-26-000013.md) | [0.4](/filings/0001099219-25-000135.md) | [0.4](/filings/0001099219-25-000193.md) | [0.4](/filings/0001099219-25-000230.md) | [0.4](/filings/0001099219-26-000050.md) | [0.4](/filings/0001099219-26-000035.md) | [0.5](/filings/0001099219-26-000050.md) |
| Shareholders' equity | $bn | [25.7](/filings/0001099219-23-000268.md) | [30.0](/filings/0001099219-25-000044.md) | [28.5](/filings/0001099219-24-000141.md) | [27.3](/filings/0001099219-24-000201.md) | [30.9](/filings/0001099219-24-000257.md) | [27.4](/filings/0001099219-26-000013.md) | [27.5](/filings/0001099219-25-000135.md) | [27.7](/filings/0001099219-25-000193.md) | [28.9](/filings/0001099219-25-000230.md) | [28.4](/filings/0001099219-26-000050.md) | [27.3](/filings/0001099219-26-000035.md) | [27.4](/filings/0001099219-26-000050.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [3,475 d](/filings/0001099219-24-000257.md) | [5,182 d](/filings/0001099219-26-000013.md) | [2,328](/filings/0001099219-25-000135.md) | [3,490 d](/filings/0001099219-25-000193.md) | [4,169 d](/filings/0001099219-25-000230.md) | [4,611 d](/filings/0001099219-26-000013.md) | [4,262](/filings/0001099219-26-000035.md) | [2,187 d](/filings/0001099219-26-000050.md) | [3,567 d](/filings/0001099219-25-000230.md) | [7,076 d](/filings/0001099219-26-000013.md) | [2,687](/filings/0001099219-26-000035.md) | [2,228 d](/filings/0001099219-26-000050.md) |
| Dividends paid | $m | [392 d](/filings/0001099219-24-000257.md) | [386 d](/filings/0001099219-26-000013.md) | [377](/filings/0001099219-25-000135.md) | [389 d](/filings/0001099219-25-000193.md) | [383 d](/filings/0001099219-25-000230.md) | [378 d](/filings/0001099219-26-000013.md) | [374](/filings/0001099219-26-000035.md) | [382 d](/filings/0001099219-26-000050.md) | [378 d](/filings/0001099219-25-000230.md) | [375 d](/filings/0001099219-26-000013.md) | [372](/filings/0001099219-26-000035.md) | [383 d](/filings/0001099219-26-000050.md) |
| Share repurchases | $m | [792 d](/filings/0001099219-24-000257.md) | [859 d](/filings/0001099219-26-000013.md) | [1,172](/filings/0001099219-25-000135.md) | [855 d](/filings/0001099219-25-000193.md) | [774 d](/filings/0001099219-25-000230.md) | [406 d](/filings/0001099219-26-000013.md) | [1,411](/filings/0001099219-26-000035.md) | [510 d](/filings/0001099219-26-000050.md) | [502 d](/filings/0001099219-25-000230.md) | [460 d](/filings/0001099219-26-000013.md) | [755](/filings/0001099219-26-000035.md) | [722 d](/filings/0001099219-26-000050.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [801](/filings/0001099219-23-000268.md) | [781](/filings/0001099219-24-000141.md) | [770](/filings/0001099219-24-000201.md) | [756](/filings/0001099219-24-000257.md) | [728](/filings/0001099219-25-000135.md) | [715](/filings/0001099219-25-000193.md) | [704](/filings/0001099219-25-000230.md) | [687](/filings/0001099219-26-000035.md) | [675](/filings/0001099219-26-000050.md) | [669](/filings/0001099219-25-000230.md) | [656](/filings/0001099219-26-000035.md) | [647](/filings/0001099219-26-000050.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 635,476,927 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001099219-26-000050.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.